Bone turnover markers in patients with osteogenesis imperfecta

被引:61
作者
Braga, V [1 ]
Gatti, D [1 ]
Rossini, M [1 ]
Colapietro, F [1 ]
Battaglia, E [1 ]
Viaplana, O [1 ]
Adami, S [1 ]
机构
[1] Univ Verona, Rheumatol Unit, I-37100 Verona, Italy
关键词
osteogenesis imperfecta; markers of bone turnover; phosphatase alkaline; osteocalcin; type I collagen; N-telopeptides; free-deoxypyridinoline;
D O I
10.1016/j.bone.2004.02.023
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Osteogenesis imperfecta (OI) is a heterologous group of rare inherited bone disorders resulting from defect in collagen synthesis or function. In previous studies, bone turnover has been found either increased or low-normal. These contradictory results might result from the study population made of children with prior recent fractures. We measured serum total and bone alkaline phosphatase (total and bone AP) serum osteocalcin (sOC), serum type I collagen C-telopeptide breakdown products (sCTX), urinary free-deoxypyridinoline (ufDPD), and urinary cross-linked N-telopeptides of type I collagen (uNTX) in 39 male and 38 premenopausal patients with different types of 01 aged between 18 and 51 years who had not experienced new clinical fracture during 12 months preceding the laboratory assessment. The study also includes a control group of 29 men and 26 women matched for age and gender. Most bone markers were 50-200% higher in patients than in controls. Only sCTX was comparable to that found in controls. From a subanalysis of the data, a trend for higher bone resorption markers was observed for any OI type, but patients with 01 type III and IV had significantly higher values in ufDPD and uNTX than patients with type 1 OI, and their sOC levels were not significantly higher than in controls. These results provide a strong rational for the use of anti-resorbing agent in OI. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1013 / 1016
页数:4
相关论文
共 16 条
[1]
Intravenous neridronate in adults with osteogenesis imperfecta [J].
Adami, S ;
Gatti, D ;
Colapietro, F ;
Fracassi, E ;
Braga, V ;
Rossini, M ;
Tatò, L .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (01) :126-130
[2]
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].
Åström, E ;
Söderhäll, S .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364
[3]
BRENNER RE, 1994, J BONE MINER RES, V9, P993
[4]
SERUM CONCENTRATIONS OF PROCOLLAGEN-I C-TERMINAL PROPEPTIDE, OSTEOCALCIN AND INSULIN-LIKE GROWTH FACTOR-I IN PATIENTS WITH NONLETHAL OSTEOGENESIS IMPERFECTA [J].
BRENNER, RE ;
SCHILLER, B ;
VETTER, U ;
ITTNER, J ;
TELLER, WM .
ACTA PAEDIATRICA, 1993, 82 (09) :764-767
[5]
Osteogenesis imperfecta: Bone turnover, bone density, and ultrasound parameters [J].
Cepollaro, C ;
Gonnelli, S ;
Pondrelli, C ;
Montagnani, A ;
Martini, S ;
Bruni, D ;
Gennari, C .
CALCIFIED TISSUE INTERNATIONAL, 1999, 65 (02) :129-132
[6]
HYPERCALCIURIA IN CHILDREN SEVERELY AFFECTED WITH OSTEOGENESIS IMPERFECTA [J].
CHINES, A ;
PETERSEN, DJ ;
SCHRANCK, FW ;
WHYTE, MP .
JOURNAL OF PEDIATRICS, 1991, 119 (01) :51-57
[7]
HYPERCALCIURIA IN OSTEOGENESIS IMPERFECTA - A FOLLOW-UP-STUDY TO ASSESS RENAL EFFECTS [J].
CHINES, A ;
BONIFACE, A ;
MCALISTER, W ;
WHYTE, M .
BONE, 1995, 16 (03) :333-339
[8]
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta [J].
Glorieux, FH ;
Bishop, NJ ;
Plotkin, H ;
Chabot, G ;
Lanoue, G ;
Travers, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (14) :947-952
[9]
Lund AM, 1998, ACTA PAEDIATR, V87, P1131
[10]
MINISOLA S, 1995, J BONE MINER RES, V10, P335